MENU
MAY 10, 2017 11:00 AM PDT

An ongoing evaluation of our transient expression systems; Can we predict the appropriate expression system for any drug modality?

Speaker
  • Scientist, Protein Technologies, Amgen, Inc.
    Biography
      Rich Altman has 29 years of experience working in the pharmaceutical industry. In 2016, he joined the Protein Technologies Mammalian Expression group at Amgen San Francisco, supporting biologics drug development. Prior to Amgen, he worked for several pharmaceutical companies on the cloning, expression, purification and characterization of recombinant proteins. This work supported both small-molecule high-throughput screening and protein therapeutic efforts. He received his MS degree from the University of Pittsburgh School of Medicine in the Department of Molecular Biology and Biochemistry.

    Abstract

    CHO cells are the predominant host for biotherapeutic protein expression with approximately 70% of licensed biologics manufactured in Chinese Hamster Ovary (CHO) cells.  The ability to express therapeutic candidates in CHO cells early in the drug development process is advantageous as it minimizes changes in protein quality and function when transitioning to production scale.  To address the lack of a robust and reproducible in-house transient CHO expression system, we incorporated the ExpiCHO™ transient expression system into our transient expression toolbox, joining the well-established HEK293-6E and Expi293™ systems.  With an ever-expanding array of protein formats, the next challenge is being able to strategically match a construct with an expression system.  We have utilized a diverse set of candidate proteins in an ongoing evaluation comparing material transiently produced in parallel in the HEK293-6E, ExpiCHO™ and Expi293™ systems for expression level and product quality.  We report these results and discuss their implications in how we prioritize our selection of expression systems.  Successful prioritization of an expression system for a drug modality will reduce parallel efforts and increase our throughput efficiency by reducing expression timelines


    Show Resources
    MAY 10, 2017 11:00 AM PDT

    An ongoing evaluation of our transient expression systems; Can we predict the appropriate expression system for any drug modality?


    Specialty

    Biotechnology

    Antibodies

    Molecular Biology

    Drug Discovery

    Cancer Research

    Gene Therapy

    Cancer Therapeutics

    Cell Biology

    Clinical Research

    Quality Control/assurance

    Biochemistry

    Pcr/rt-Pcr/real-Time Pcr

    Diabetes

    Genetics

    Systems Biology

    Geography

    North America53%

    Asia21%

    South America18%

    Europe3%

    Africa3%

    Registration Source

    Website Visitors100%

    Job Title

    Scientist21%

    Research Scientist18%

    Student14%

    Executive7%

    Educator/Faculty7%

    Biologist7%

    Lab Management7%

    QC/QA4%

    Genetic Counselor4%

    Medical Doctor/Specialist4%

    Medical Laboratory Technician4%

    Facility/Department Manager4%

    Organization

    Biotech Company18%

    Academic Institution9%

    Clinical Laboratory9%

    Private Practice3%

    Industrial Company3%

    Research Institute3%

    Manufacturer & Biotech/pharma3%

    Manufacturer - Other3%

    Distribution/sales3%

    Life Science Company3%


    Show Resources
    Show Resources
    Attendees
    • See more
    Connect with us